Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...
Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...
According to the scientists, study participants had fewer days to recover from the illnesses when compared to the standard of ...
LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key MetricsFindings Highlight ...
which is nearing initiation of Phase 2 clinical trial in patients with moderate-to-severe rheumatoid arthritis, and a Phase 2a clinical trial for an additional autoimmune indication. Uvax Bio ...
Düsseldorf, Germany Wednesday, February 5, 2025, 18:00 Hrs [IST] ...
Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) climbed 10% following the announcement of a significant clinical response ...
LLC ("Zina") to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease. Under the terms of the agreement, Zina will provide comprehensive services related to ...
Ethris Presents Positive Topline Phase 1 Data with mRNA Lead Candidate ETH47 for Uncontrolled Asthma
Based on the encouraging Phase 1 results, Ethris filed a Clinical Trial Application (CTA) for a Phase 2a rhinovirus challenge study in asthma patients, planned to begin in Q2 2025. This upcoming ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback